The prevalence of carriage of antimicrobial-resistant (AMR) and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli was determined in 183 healthy dogs from a semi-rural community in Cheshire. Isolates were tested against a panel of antimicrobials and by PCR to detect resistance genes. In the suspected ESBL-producing isolates, the presence of bla SHV , bla TEM , bla CTX-M and bla AmpC genes was determined by PCR and sequencing. 
mechanism, due to their broad spectrum of resistance to β-lactams and the ineffectiveness of β-lactamase inhibitors, are plasmid-mediated AmpC enzymes (Philippon and others 2002) .
Escherichia coli can be readily isolated from the gastrointestinal tract of many animal species, including human beings and dogs, and is therefore a good indicator of reservoirs of AMR (van den Bogaard and Stobberingh 2000) . The presence of E coli in the intestinal tract of human beings, dogs and most animal species results in its exposure to any antimicrobial agents that are administered and that enter the gastrointestinal tract. This exposure can select for E coli that have acquired resistance determinants or mutations encoding AMR. In addition, there is the potential for AMR E coli to act as a reservoir of resistance determinants for pathogenic bacteria (Guardabassi and others 2004) .
A significant quantity of antimicrobials sold in the UK are for veterinary use (VMD 2000) . Since 2002, total veterinary sales of therapeutic antimicrobials have decreased (from 440 tonnes in 2002 to 387 tonnes in 2008); however, the total sales of drugs indicated for use in non-food-producing animals only has increased, with a notable rise in sales of therapeutic antimicrobials licensed for use in dogs only (from 4.5 tonnes in 2002 to 7.3 tonnes in 2008) . Increased use of antimicrobials in dogs, coupled with selection pressures for resistance, may result in higher carriage of AMR bacteria.
People and dogs are often in close contact, and as a result there is a risk of transfer of bacteria, resistant or otherwise, from one to the other, which may influence the success of the antimicrobial treatment required by the individual if the bacteria cause disease. AMR E coli have been isolated from clinical samples from dogs (Normand and others 2000a, b) and other animals (Lanz and others 2003) . In addition, faeces from healthy dogs others 2004, Costa and others 2008) and various other animals (Moyaert and others 2006) have been shown to harbour AMR E coli. ESBL-producing E coli have been isolated from both healthy dogs and those with asked to provide a fresh faecal sample from their dog and complete a short questionnaire relating to medical history (eg, recent history of vomiting, diarrhoea and antimicrobial use). Faecal samples were obtained from 183 healthy dogs over a period from August to November 2005. The fresh faecal samples were mixed with an equal volume of brain heart infusion broth with 5 per cent glycerol and the homogenate was stored at below -70°C. The faecal homogenates were thawed and processed as described below.
Isolation and identification of E coli
AMR E coli were detected using the direct plating method previously described by others (1998, 2006) . Thawed faecal homogenate was plated directly on to MacConkey's agar and eosin methylene blue agar (EMBA) using a plain cotton swab, and the following antimicrobial discs (MAST Group) were applied: 10 μg ampicillin, 30 μg amoxicillin-clavulanate, 30 μg chloramphenicol, 1 μg ciprofloxacin, 30 μg nalidixic acid, 30 μg tetracycline and 2.5 μg trimethoprim. After overnight incubation at 37°C, colonies growing within the zone of inhibition around each disc on both sets of plates, whose morphology resembled E coli were selected for subsequent investigation. To screen for ESBL-producing E coli, the faecal homogenates were directly streaked on to EMBA containing 1 μg/ml ceftazidime and EMBA containing 1 μg/ml cefotaxime (Sigma-Aldrich) (Liebana and others 2006) . In addition, to allow for non-selective isolation of E coli, faecal homogenates were also directly streaked on to EMBA containing no antimicrobials. Three isolates from this plate were selected for subsequent antimicrobial testing. Presumptive E coli resistant to at least one antimicrobial were confirmed by biochemical testing (Gram stain and testing for catalase production, lack of oxidase, lactose fermentation, indole production and inability to use citrate as a carbon source) and uidA PCR (McDaniels and others 1996) . All media were supplied by Lab M.
Antimicrobial susceptibility testing
Antimicrobial disc diffusion testing was performed in accordance with British Society of Antimicrobial Chemotherapy guidelines (Andrews 2007) . The following antimicrobial discs were used: 10 μg ampicillin, 30 μg amoxicillin-clavulanate, 30 μg chloramphenicol, 1 μg ciprofloxacin, 30 μg nalidixic acid, 30 μg tetracycline and 2.5 μg trimethoprim. For the isolates suspected of ESBL production, a further panel of nine antimicrobial agents was also tested: 30 μg aztreonam, 30 μg ceftazidime, 30 μg ceftriaxone, 30 μg cefoxitin, 30 μg cefuroxime, 30 μg cefalexin, 25 μg trimethoprim-sulfamethoxazole, 10 μg gentamicin and 10 μg tazobactam/75 μg piperacillin. The reference strain E coli ATCC 25922 was used for quality control during testing.
Phenotypic confirmation of ESBL production
Isolates that were selected from the cephalosporin-containing EMBA plates, and therefore suspected of ESBL production, were tested using the MAST double disc diffusion method previously described by M'Zali and others (2000) . Briefly, an Iso-Sensitest agar plate was inoculated with the isolate, and three pairs of cephalosporin discs (with clinical infections (Moreno and others 2008) . However, with one exception in Sweden (SVA 2006) , previous studies investigating AMR E coli in healthy dogs have been limited in their sample size, and in some countries, including the UK, no such studies have been published.
The aim of the present study was to determine the prevalence of AMR E coli and ESBL-producing E coli in the faeces from healthy dogs in a census-based, cross-sectional study of a community in Cheshire.
Materials and methods

Collection of faecal samples
Details of the sample population and faecal sample collection from dogs in a semi-rural community in Cheshire have been previously described by others (2007, 2009) . Briefly, in a census-based study of 1278 households, 260 were identified as dog-owning. Owners were Papers up system (Promega), and sequenced on both strands with additional primers used for the internal sequence (two for bla CMY sequencing and three for bla TEM sequencing) (Mocktar and others 2008) . The sequences were compared with those in GenBank (http://blast.ncbi.nlm.nih. gov/Blast.cgi) to obtain the specific bla CMY and bla TEM gene variants.
Results
A total of 69 unique AMR E coli isolates were collected from the faeces of 53 (29 per cent, 95 per cent confidence interval [CI] 22.4 to 35.5 per cent) of the 183 dogs tested in the study. Thirteen dogs were found to be carrying more than one unique isolate of E coli with differing AMR profiles. The susceptibility of isolates to seven antimicrobial agents is shown in Table 2 . Twenty-four per cent of dogs (95 per cent CI 17.9 to 30.2 per cent) harboured at least one isolate with ampicillin resistance, 19.7 per cent (95 per cent CI 13.9 to 25.4 per cent) with tetracycline resistance, and 16.9 per cent (95 per cent CI 11.5 to 22.4 per cent) with trimethoprim resistance. The percentage of dogs with E coli resistant to the other antimicrobials tested was less than 4 per cent. Twenty-seven (14.8 per cent, 95 per cent CI 10.1 to 20.5 per cent) of the 183 dogs sampled harboured at least one multidrug-resistant (MDR) (resistant to three or more antimicrobial classes) isolate. Thirty (44 per cent) of the 69 AMR E coli isolates were shown to be MDR and 19 (28 per cent) were resistant to two antimicrobial classes. The resistance profiles of the 69 isolates are shown in Table 3 . The most common resistance profile was ampicillin-tetracycline-trimethoprim resistance, which was found in 26 per cent of the isolates, followed by ampicillin-only and tetracycline-only resistance, both of which were found in 13 per cent of isolates each, and ampicillin-trimethoprim and ampicillin-tetracycline resistance, which were found in 10 per cent of isolates each.
Only one dog, which was found not to carry AMR E coli, was recorded as being on a course of antimicrobials when the faecal sample was collected. Of 15 dogs reported to have had a course of antimicrobials in the previous month, five (33 per cent) carried AMR E coli. This was also true for nine of 37 (24 per cent) dogs whose owners reported antimicrobial use in the previous year. A similar prevalence, however, was observed among the dogs with no reported antimicrobial use.
The presence of dfr genes was investigated in the isolates resistant to trimethoprim; of 33 trimethoprim-resistant isolates, 11 were found to harbour dfrA1, eight had dfrA5 and three had dfrA14 genes. The remaining 11 trimethoprim-resistant isolates were negative for these genes in addition to dfrA7, A8, A9, A12, A13 and A17. Of the 45 isolates resistant to tetracycline, 12 were found to harbour tet(B), and none of the tet genes tested (tetA, B, C, D, E and G) could be detected in the remaining 33 isolates. Of the 54 ampicillin-resistant isolates, 39 were found to harbour a bla TEM gene and none was positive for the detection of a bla SHV gene. No qnr genes were detected in any of the isolates tested, including those resistant to nalidixic acid.
Results relating to the nine E coli isolates selected from the plates screening for ESBL production are shown in Table 4 . Only one isolate was confirmed using the MAST double disc diffusion method as an ESBL-producer. A variety of resistance phenotypes were observed in these isolates, with only two sharing the same resistance profile. The nine isolates were tested for the presence of β-lactamase enzymes. A bla TEM gene was detected in two isolates, which were identified as bla TEM-1 by sequencing. In seven isolates, bla AmpC was detected and all were identified as the bla CMY-2 gene. No bla CTX-M or bla SHV genes were amplified from any of the isolates. A bla CMY-2 gene was found in the only isolate to test positive for ESBL production, but none of the other genes tested was found.
Discussion
This study aimed to estimate the prevalence of AMR E coli carriage in a community of healthy dogs, and found that AMR carriage was widespread in the dogs sampled (29 per cent). MDR E coli was also found in these dog samples (14.8 per cent). The most common antimicrobials that the isolates were resistant to were ampicillin, tetracycline and trimethoprim. This is also reflected in the most common resistance phenotype observed and might reflect the mobile nature of the genes responsible for these resistance phenotypes, and that there are numerous variants of these resistance genes. and without clavulanic acid) were placed on the surface of the agar plate: 30 μg ceftazidime and 30 μg ceftazidime plus 10 μg clavulanic acid; 30 μg cefotaxime and 30 μg cefotaxime plus 10 μg clavulanic acid; and 30 μg cefpodoxime and 30 μg cefpodoxime plus 10 μg clavulanic acid. The plates were incubated aerobically at 37°C for 18 to 24 hours and zone diameters around each disc were measured. ESBL production was confirmed when the zone around the cephalosporin disc was expanded in the presence of the clavulanic acid by a minimum of 5 mm, according to the manufacturer's instructions (MAST Group). The AmpC phenotype was suggested when the presence of clavulanic acid did not result in an increase in the zone of inhibition. , dfrA5, dfrA7, dfrA8, dfrA9, dfrA12, drfA13, dfrA14 and dfrA17 genes (Gibreel and Sköld 1998, Lee and others 2001) . In addition, the presence of qnrA, qnrB and qnrS genes were tested by PCR in all isolates. Finally, isolates resistant to tetracycline were screened by PCR for the following genes: (Ng and others 2001) . Conditions and references for each PCR assay are shown in Table 1 . A positive control (an isolate known to carry the gene under investigation) was included in each PCR assay.
Characterisation of AMR genes
tet(A),
tet(B), tet(C), tet(D), tet(E) and tet(G)
Sequencing of bla CMY and bla TEM genes
For sequencing of the bla CMY gene, oligonucleotide primers were used to amplify the entire gene (Liebana and others 2004) . For bla TEM sequencing, the amplicon was obtained using the primers for initial detection. The amplicons were cleaned using the Wizard SV gel and PCR clean- 
Papers
The prevalence of ampicillin resistance observed was higher than previously reported in healthy dogs in Portugal (Costa and others 2008) , but similar to a study investigating, among others, healthy cat populations (Moyaert and others 2006) . Resistance to other antimicrobials (amoxicillin-clavulanate, chloramphenicol, quinolones, tetracycline and trimethoprim) was comparable across all three studies. The resistances observed in the present study are much higher than reported in a study of healthy dogs in Sweden (SVA 2006) , which may reflect differences in methodology. It is important to note that the dogs sampled in the present study were considered healthy based on questionnaire responses made by the owners, which may differ from other study definitions of 'healthy'. When compared with studies investigating clinical isolates, resistance to ampicillin (Normand and others 2000a) and tetracycline (De Graef and others 2004) was lower in the current population. Resistance to other antimicrobials was similar. In clinical isolates of E coli from dogs in Denmark, the prevalence of AMR was comparable for all antimicrobials with the exception of nalidixic acid, which was higher in the Danish study (12.5 per cent v 3.3 per cent in the present study) (Pedersen and others 2007) . Differences in the prevalence of resistance observed may be due to differences in the interpretation of the zone sizes or minimum inhibitory concentrations observed, or differences in how intermediate measurements were classified. This highlights how difficult it can be to compare different studies when a variety of methodologies and guidelines of interpretation are used and emphasises the need for more standardised methods. This may prove difficult to achieve both on an international level and between the medical and veterinary professions. However, it is likely that, compared with isolates from clinical cases, the apparently healthy household dogs sampled in the present study would have had less exposure to antimicrobials and hospital environments, both of which have been shown previously to increase the prevalence of AMR (Dunowska and others 2006, Moreno and others 2008) .
The gene responsible for conferring trimethoprim resistance could be determined in only 22 of the 33 isolates tested; the genes dfrA1, dfrA5 and dfrA14 were detected and have been previously described in E coli isolates of animal origin others 2004, Cocchi and others 2007) and also from human isolates (Lee and others 2001) . Only tet(B) was detected in the tetracycline-resistant isolates, which has been found in other isolates from animals (Sáenz and others 2004 , Costa and others 2008 , Enne and others 2008 . The isolates that were negative for the genes tested are likely to harbour other genes responsible for trimethoprim and tetracycline resistance that were beyond the scope of this study and not tested.
The qnrA, qnrB and qnrS genes were not detected in any isolates. These genes are responsible for low-level resistance to quinolones (Martínez-Martínez and others 1998). In addition to the qnr genes, other mechanisms of quinolone resistance may be involved to give higher levels of resistance, for example, mutations in the genes encoding the subunits of DNA gyrase (gyrA and gyrB) or topoisomerase IV (parC and parE) (Piddock 1998) .
In total, nine suspected ESBL-producing isolates were recovered. Subsequent testing confirmed only one of these to be positive for ESBL production but, as shown in Table 4 , the only gene detected by PCR was a bla CMY-2 gene. It is possible that this isolate carried a type of ESBL not tested in the present study, for example, an OXA-or VIMtype ESBL. Among the eight other isolates, two carried bla TEM-1 genes, and six carried the plasmid-mediated AmpC bla CMY-2 gene. Bla CMY genes have previously been reported in isolates from dogs others 2006, 2007) .
In summary, the present study demonstrates a common occurrence of AMR, in particular MDR, among the faecal E coli of healthy dogs living in the community, with a variety of mechanisms responsible for resistance. This is of concern, given the close and frequent contact dogs have with people, and could pose a risk for the spread of resistant bacteria or resistance genes. Larger studies are required to more accurately estimate the prevalence of AMR E coli in healthy dogs, and thus fully understand both the risk factors for resistance and any risks posed to people. It would also be prudent to carry out longitudinal studies to investigate whether AMR is maintained over time and how this relates to antimicrobial prescribing practices. 
